• Leading the research and technology development of world-changing drug delivery platform technologies for improving patient outcomes in oncology, gene therapy, and immunotherapy.• Managing a pipeline consisting of an IND-cleared local pancreatic cancer drug delivery solution, a preclinical stage recurrent oral cavity cancer drug delivery solution, and a research-stage drug-resistant skin melanoma technology.• Spearheaded the rebranding of Advanced Chemotherapy Technologies, Inc. to Focal Medical, Inc., positioning the company for future growth and success.

• Supporting the Maana Discoveries team in developing innovative biomaterial, tissue scaffold, and drug delivery platforms.• Collaborating with cross-functional teams to accelerate product development and commercialization.• Implementing strategic initiatives to drive growth and market penetration for novel technologies.

• Leading a specialty consulting practice in medical device development, focusing on design, verification, validation, and commercialization.• Utilizing rapid prototyping and design thinking to translate customer insights into high-quality design inputs.• Manage R&D projects, identify new opportunities, and provide regulatory support for medical devices.

• Leading the development of innovative medical device concepts using additive manufacturing technologies to address unmet medical needs.• Collaborating with patients, providers, and payers to identify insights and value drivers for game-changing solutions.• Currently focused on improving outcomes for peritoneal dialysis patients and exploring new solutions for endometriosis and arthroplasty procedures.

• Advising Rilento Pharma on technical development and scale-up of a novel oral surgery pain management technology platform.• Helping the team obtain critical intellectual property filings and advance technology into the clinical testing phase.• Assisting the team in fundraising efforts through grants and investments.

Serving as a mentor in the Blueprint MedTech program, leading technology deep dives and mentoring applicant companies.

• Team Leader for the RADx initiative, providing rapid development and regulatory support to over 20 companies for innovative COVID-19 testing technologies.• Collaborated with professionals to bring new testing approaches to the NIH, aiding in the fight against the pandemic.

I am currently leading the technology development of a novel pancreatic cancer drug delivery device that was developed and spun out of the University of North Carolina at Chapel Hill, getting it ready for first in human clinical trials.

Site leader of the Allergan Medical facility in Medford Massachusetts. Also head of R&D responsible for leading a multidisciplinary team of scientists and engineers, focusing on new product and process development of silk-based biomaterials for soft tissue repair and reinforcement. Primary responsibility is directing fundamental and applied R&D projects, new opportunity identification and product development, aligned with the strategic pipeline and portfolio planning process. Additionally responsible for new process development and scale-up, product and process modelling and simulation, pilot and pivotal preclinical in-vitro and in-vivo investigations, as well as evidence generation studies, commercialization and manufacturing support of the SERI® Surgical Scaffold platform.Significant Achievements: Record breaking design, development, validation and technology transfer of SERI Surgical Scaffold; Successful Tech transfer of manufacturing process from Medford Massachusetts to Westport Ireland; Reduced scale up and validation of next generation SERI surgical scaffold product by six months; Successful leadership of Medford facility during Actavis acquisition of Allergan (all company goals met or exceeded simultaneously with change management initiatives).

Responsible for leading a multidisciplinary team of scientists and engineers at the Allergan Medical facility in Medford, MA, focusing on new product and process development of silk-based biomaterials for soft tissue repair and reinforcement. Primary responsibility is supporting scale-up, evidence generation and commercialization of SERI™ Surgical Scaffold.

After Closure Medical was acquired by Ethicon, promoted to Product Development Director. Responsible for leading Ethicon New Product Development (chemical development, formulation, analytical and preclinical) in the rapid development and commercialization of robust synthetic biosurgical adhesive and sealant medical devices. Developed extensive disease state understanding and expertise in vascular surgery and repair, plastic and reconstructive surgery, neurosurgery, orthopedics and laparoscopic surgery. Responsible for four business critical product launches supporting a combined 400MM technology portfolio across three Ethicon businesses (Biosurgicals, Aesthetics and Wound Management). Three business critical regulatory approvals (510(k), PMA). Extensive multi-location organizational management and people development. Development, FDA and CE Mark approval, US and OUS commercialization of Ethicon™ OMNEX™ Surgical Sealant. Development, FDA and CE Mark approval and US/OUS commercialization of PRINEO™ Skin Closure System. Development, FDA approval and US commercialization of DERMABOND ADVANCED® Topical Skin Adhesive.

Promoted to manage diverse group of chemists, polymer scientists and analytical chemists in the development of topical and internal absorbable synthetic biosurgical adhesives and sealants. Technology development for (4) Ethicon businesses, from consumer to professional medical. Development, CE Mark and European commercialization of PRINEO™ Skin Closure System™.

Leader of a small group of scientists in the development and commercialization of synthetic biosurgical adhesive and sealant products and processes. Development, CE Mark and European commercialization of Ethicon™ OMNEX™ Surgical Sealant. Development, CE Mark and European commercialization of DERMABOND Mini™ Topical Skin Adhesive.

Operations and Support Director of a nuclear magnetic resonance spectrometer service, support and instrument brokering start-up company. Responsible for strategic business plans, finance, customer support and marketing presence. Coordinated due-diligence process during acquisition attempt.

Polymer scientist responsible for the materials R&D related to the development of a state-of-the-art prosthetic heart valve.Research, development and verification testing of novel implantable cardiovascular biomaterial (Elasteon). Development of a state-of-the-art, wholly synthetic aortic replacement heart valve. Biocompatibility and safety testing of cardiovascular biomaterials. Troubleshooting and stabilization of the Elasteon polymerization and manufacturing process in Melbourne, Australia.

Product development scientist in the Coatings, Adhesives, Sealants and Elastomers group, responsible for developing and commercializing polyurethane-based elastomer and adhesive/sealant products.After the ICI Polyurethanes division was acquired by Huntsman Chemical, promoted to Project Leader to develop amd commercialize a proprietary polyurethane chemistry concept that imparted novel and commercially relevant properties to polyurethane thermoplastic elastomers. Developed and commercialized thermally stable automotive engine components.

Senior Research Scientist responsible for fundamental R&D and the development of new polyurethane technology platforms. Developed new polyurethane technology platform (SMoCE™) based on controlled phase separation and hard segment development that supported commercial innovations in low density foams and high performance thermoplastic elastomers.

Senior analytical chemist in charge of chemical characterization of polymers and elastomers (worked full-time while attending undergraduate university).

Summer intern researching TiO2 pigment replacements and new pigment particle morphologies to enhance hiding and impact characteristics of industrial coatings.